Just a summary of all the news articles that we could source from different places. A good way to make an investment decision is also to look at how actively the company is engaging with news sources to keep them in the news. In this day and age its critical to have a media presence.
Please consider a small donation if you think this website provides you with relevant information
| Date | Title | Source |
|---|---|---|
| 2024-03-22 12:29:58 pm | Invivyd Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical Trial | GlobeNewsWire |
| 2024-03-22 12:4:0 pm | Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19 | GlobeNewswire |
| 2024-02-05 1:2:0 pm | Invivyd to Participate at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference | GlobeNewswire |
| 2024-01-29 9:35:14 am | 3 Groundbreaking Biotech Stocks to Invest in Now | InvestorPlace |
| 2024-01-19 4:33:44 am | When Will Invivyd, Inc. (NASDAQ:IVVD) Become Profitable? | Simply Wall St. |
| 2024-01-12 9:0:6 am | All You Need to Know About Invivyd, Inc. (IVVD) Rating Upgrade to Strong Buy | Zacks |
| 2024-01-03 4:0:0 am | Invivyd Submits Request for Emergency Use Authorization (EUA) to U.S. FDA for VYD222 for the Pre-exposure Prevention of COVID-19 in Immunocompromised Adults and Adolescents | GlobeNewswire |
Please consider a small donation if you think this website provides you with relevant information